---
title: "Saroglitazar: Primary biliary cholangitis"
description: "Formulary evidence on Saroglitazar in Primary biliary cholangitis. Clinical evidence covers EPICS-III, EPICS-IV, EPICS-V, EPICS, Open-label single-arm study, SARO.23.002, and 9 further headings. 267 evidence topics quoted from 79 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Saroglitazar: Primary biliary cholangitis

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Saroglitazar

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Primary biliary cholangitis

<a id="topic-1.1.1-1"></a>

##### Summary

The adjusted U.S. prevalence of PBC in 2021 was 40.9 per 100,000 adults, corresponding to an estimated 105,506 adults. In the ITCH-E study, activity impairment was 57% in the moderate-to-severe pruritus group versus 36% in the no or mild pruritus group. A separate observational analysis reported one-year adjusted healthcare costs of $39,949 with pruritus versus $25,695 in controls. These observational comparisons describe disease burden rather than treatment effects.

Source: [Levy et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11999412/); [Levy et al. (2025c)](https://onlinelibrary.wiley.com/doi/full/10.1111/liv.70276); [Gish et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1002/lci2.70044)

<a id="heading-1.1.2"></a>

#### 1.1.2 Saroglitazar Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

In the phase 3 portion of EPICS-III, 148 participants were randomized. The sponsor reported biochemical response at week 52 in 56.7% receiving saroglitazar and 9.8% receiving placebo. Serious adverse events were reported in 6.3% and 11.1%, respectively. The EASL Congress report described a statistically significant pruritus improvement at six months that was not maintained at 12 months. These results support a biochemical treatment effect but do not establish a reduction in liver transplantation or mortality.

Source: [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf); [EASL Congress (2026)](https://www.easlcongress.eu/wp-content/uploads/2026/05/Media-Release_scientific-2026_28-May_none-1.pdf)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Saroglitazar

<a id="topic-1.1.3-1"></a>

##### Summary

The report contains an illustrative managed-access model for the Spanish National Health System, available as a preprint abstract. It assumes a net price of €25,000 per year and reports modeled net health-system costs of €4,371,005 over 24 months, with €586,495 in savings relative to its modeled price without risk sharing. These are model assumptions and outputs, not an announced commercial price or a U.S. budget-impact estimate.

Source: [Poey (2026)](https://doi.org/10.2139/ssrn.6968638)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

Saroglitazar remains investigational for PBC in the United States. The sponsor reports Priority Review with a PDUFA target action date of November 27, 2026. The proposed population consists of adults with an inadequate response to UDCA, or patients unable to tolerate UDCA. The available phase 3 evidence primarily addresses biochemical response over 52 weeks; longer-term clinical benefit remains to be established.

Source: [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=686819); [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf); [Zydus Therapeutics (2026)](https://www.prnewswire.com/news-releases/zydus-therapeutics-new-drug-application-nda-for-saroglitazar-to-treat-primary-biliary-cholangitis-pbc-granted-priority-review-by-the-us-fda-302784488.html)

## Related pages
- [Saroglitazar in Primary biliary cholangitis: Terms and abbreviations](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/terms-and-abbreviations.md)
- [Saroglitazar: Primary biliary cholangitis](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/executive-summary.md)
- [Saroglitazar in Primary biliary cholangitis: Product information and disease description](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/product-information-and-disease-description.md)
- [Saroglitazar in Primary biliary cholangitis: Clinical evidence](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/clinical-evidence.md)
- [Saroglitazar in Primary biliary cholangitis: Economic information and modeling report](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/economics) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/economics.md)
- [Saroglitazar in Primary biliary cholangitis: References](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/references) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/references.md)
- [Saroglitazar in Primary biliary cholangitis: prevalence by geography](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/prevalence) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/prevalence.md)
- [Saroglitazar in Primary biliary cholangitis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/cost-effectiveness-analyses.md)
